1 Shank PR, Gardocki JF, Streeter AJ, et al.An overview of the preclinical aspects of topiramate:pharmacology, pharmacokinet-ics, and mechanism of action[J].Eplepsia, 2000;41:S3-9
2 罗时才.抗癫痫新药———托吡酯[J].中国药学杂志, 2000;35:496-8
3 Langtry HD, Gillis JC, Davis R.Topiramate:a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacyin the management of epilepsy[J].Drugs, 1997;54: 752-3
4 Doose DR, Walker SA, Gisclon LG, et al.Single-dose pharma-cokinetics and effect offood on the bioavilability of topiramate, a novel antiepileptic drug[J].J Clin Pharmacol, 1996;884-91
5 Doose DR, Gisclon LG, Stellar SM, et al.The effect offood on the bioavailability of topiramate fiom 100 and 400 mg tablets inhealthy malesubjects[J]. Epilepsia, 1992, 3305
6 赵忠新,黄坚,抗癫痫新药托吡酯临床应用研究进展[J],中国新药与临床杂志,2001;20: 65-7
7 Gisclon LG, Curtin CR, Kramer LD.The steady-state(ss) phar-macokinetics(pk) of phenytoin of (Dilantin) and topi amate(Topamax) in topiramate in epleptic patients on monotherapy,and during combination therapyf J. Epilepsia, 1994; 3548
8 Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients withepilepsy duing monotherapy and oncomitant therapy[J].Epilepsia, 1996; 37; 774-80
9 Rosenfeld WE, Liao s, Kramer LD,et al. Comparison of thesteady-state phamnaooki netics of topiramate and valproate in patients with epilepsy during monothenapy and comcomitant therapy[J]. Epilepsia, 1997; 38(3):3243
10 Johnnessen SI. Phamacokinetics andintenction profile of topi-ram atereview and comparison with other newer antiepilepticdrugfJ. Epilepsia, 1997; 38, S18 S23
11 Doose DR, Rosenfeld WE, SchaeferP, et al. Evaluation of thepotential phamacok inetic interaction betw cen topiramate and theomal contraceptive cmbination norethin drone/ethinyl estradiol[[J]. J Clin phamaool, 1995; 34, 1031
12 TakeckaM, Hamles GL, Thiele E, et al. Topiramate andmetabolic acidosis in pediatic epilepsy[J]. Epilpia, 2001;42).3872
13 Shank RP, Gardocki JF, Vaught JL, et al.Topiramate; predini-cal evaluation of a structurally novel anticonwulsanf [J]. Epilep-sia, 1994; 35: 450-60
14 Rosenfeld WE, Doose DR, WalkerSA, et al. A study of topira-mate phamacokinetics and tolerability in children with epilepsy[J]. PediatrNeurol, 1999; 20: 339-44
15 Gisclon IG, Riffits M, Sica DA, et al. The pharmacokineticsof topiramate in subjects with renal impai ment as compared tomatched subjects with nomal renal function[J]. Pham Res,1993; 10: S397
16 Gibbs III Jw, Sombatis, Delorenzo RJ, et al. Cellular actionsof topiramate:blockade of kainite-evokedinward curents incultured hippocmpal neurons[J]). Epilepsia, 2000; 4l: S10-S16
17 White HS, Brown SD, Woodhead JH, et al. Topiramate mod-ulates GABA evoked currents in munine cortical neuons by anonbenzoliavepine mechamim[J]·Epilepsia, 2000; 4l:S17-S20 |
